Buddy Lyons
Value, long/short equity, contrarian, growth

Momenta: Impending Approval Provides Price Support With Excellent Upside Potential

Despite the run-up in Momenta (NASDAQ:MNTA) over the past year and the recent announcement that Baxter (NYSE:BAX) is dropping Momenta's lead biosimilar compound, we believe there is still considerable upside remaining over the next 12-24 months. Momenta's impending approval of M356 (generic Copaxone - TEVA) with Sandoz with equal profit-sharing should drive shares higher assuming a May launch (when patents expire). The company's unique ability to characterize biologics may give it an edge in the biosimilar market by enabling the company to avoid large trials, shortening time to market, and the possibility of being deemed interchangeable with the reference biologic. Its partnership with Baxter to supply biosimilars provides it a major player for commercialization and may...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details